Key Takeaways
- Underlying growth intact despite optics: Reported domestic sales grew 3%, but stripping out the NLEM impact reveals 8% growth, which management calls significant for the quarter.
- Portfolio reshaped through partnerships and launches: Sanofi handed its CV and CNS established brands to Emcure and Cipla for distribution and promotion, while launching Soliqua into the INR1,000 crores premix insulin segment where it previously had no presence.
- Diabetes franchise now covers every insulin segment: With Lantus, Toujeo, Soliqua and locally produced Insutage, Sanofi fields a portfolio spanning basal, premix and human insulin, and expects Lantus volume expansion to accelerate post-NLEM.
- CHC demerger is on the cusp: The consumer healthcare listing is expected in the next few months, with the organization being built around portfolio enhancement, digital capabilities and inorganic opportunities.
- What to watch next quarter: The CHC listing date, early Soliqua prescription trends, and any volume acceleration in Lantus now that the NLEM price reduction is fully absorbed.
Domestic Performance & the NLEM Overhang
- Reported vs. underlying: The 3% reported domestic growth reflects the NLEM price cut implemented in April 2023; excluding that impact, underlying growth was 8%, which management characterizes as significant for a single quarter.
- Profit consistency: Profit before exceptional items and tax at INR215 crores in Q1 2024 remains one of the highest across all quarters of the prior year, and expenses were held flat with certain savings realized from the go-to-market pillar of the India for India plan.
- Comparability caveat: Q1 2024 and Q1 2023 are not directly comparable because the base quarter included a 30% export surge driven by volume and favourable FX, exceptional other income of ~INR19 crores from interest and tax items, and ~INR18 crores from asset sales.
Hrosz: "We outlined this plan back at the end of 2022 and we continue to walk that talk. So this is what we said we would do. And we've been consistent in progressing against those four pillars."
Strategic Partnerships: CV to Emcure, CNS to Cipla
- Structure: These are distribution and promotion agreements, not out-licensing deals. The partners take charge of both marketing and distribution through their own field forces, which are larger than what Sanofi could deploy itself, extending reach into Tier 2, Tier 3 and Tier 4 cities.
- Revenue model: Sanofi operates a gross-to-net model: it bills the partner and books net sales in its own books, while all marketing and distribution expenses sit at the partner level. The impact is already absorbed in operating profit and was evaluated as accretive to shareholder value on a net present value basis.
- Growth thesis: Management expects accelerated growth from these iconic brands because of the expanded capillarity and reach the partners provide, freeing Sanofi to focus on bringing new best-in-class and first-in-class therapies to market.
- What was not disclosed: Management declined to provide margin impact by brand or brand group, current MR headcount, or whether the reported rationalization of 500-550 employees was tied to these deals.
Hrosz: "It's not an un-licensing deal. It's a distribution and promotion deal."
Diabetes: Soliqua Entry & Portfolio Completion
- Soliqua fills a gap: Soliqua is a best-in-class therapy entering the premix insulin segment, a market of INR1,000 crores, roughly the same size as the basal segment where Sanofi already competes with Lantus and Toujeo. Sanofi previously had no product capturing patients migrating from basal to premix insulin.
- Leadership ambition: Management believes Soliqua has the strength to achieve leadership in the premix segment. First-month results from the April launch were in line with and slightly above high expectations.
- Lantus post-NLEM: The NLEM price reduction is seen as an opportunity for Lantus to expand penetration and grow volume; volume expansion is already visible and expected to accelerate and be sustained for a prolonged period.
- Full insulin coverage: Sanofi now fields Lantus, Toujeo, Soliqua and Insutage (locally produced human insulin, replacing Insuman), catering to each key insulin segment in the Indian market.
- Pipeline: Sanofi Group acquired Prevention Bio, which developed TZIL, a first-in-class therapy for type 1 diabetes; Sanofi intends to bring that product to the Indian market, though no launch timeline was given.
Hrosz: "INR1,000 crores, which is the same size of the market where we compete with Lantus and Toujeo, right? It's a very large market where we don't compete. And we believe Soliqua has the strength to achieve leadership in that segment of premix."
Consumer Healthcare: Demerger & Building Blocks
- Listing imminent: The CHC demerger governance transition is on track, with listing expected in the next few months; management will engage investors for a detailed discussion on CHC plans at that point.
- Four building blocks underway: Portfolio enhancement through deeper penetration, modern OTC regulation advocacy and innovation; a consumer-centric mindset built on insights, awareness-driving and modern trade presence; best-in-class digital and e-commerce capabilities including global CHC data and digital tools; and active evaluation of inorganic growth opportunities and direct-to-consumer brand activation.
- Category focus: Most launches and focus will remain on the core categories of allergy, physical wellness and pain, though new brands from the global portfolio will be evaluated.
- OTC regulation opportunity: Draft OTC regulations are still under discussion with the government; once finalized, management sees significant opportunity to evolve distribution and consumer engagement, allowing more direct consumer education and business-driving activity.
India for India Plan & Local Innovation
- All innovation milestones checked green: Frisium, SANOXABAN, Carmada, Soliqua, Insutage and Cetapin S have all been launched; Allegra is next, coming through the merger.
- Localization strategy intact: Sanofi will continue leveraging India's industrial footprint, localizing more production and launching local innovations.
- CHC performance: Very strong Q1 across all key brands despite a challenging market, with significant share gains in allergy, physical wellness and pain.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CHC listing | Demerger completed, FMCH organization established, shares listed | Next few months |
| Lantus volume expansion | Volume growth to accelerate and be sustained for a prolonged period post-NLEM price reduction | Already visible, expected to sustain |
| Soliqua market leadership | Achieve leadership in the INR1,000 crores premix insulin segment | No date; "coming months and years" |
| TZIL launch | First-in-class type 1 diabetes therapy brought to Indian market | No date given |
| Allegra launch | Next innovation in the India for India plan, coming through the merger | Post-merger |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Domestic retained sales | ₹566 cr, +3% YoY reported, +8% YoY excluding NLEM impact |
| Profit before exceptional items and tax | ₹215 cr, -12% YoY from ₹246 cr in Q1 FY23, double-digit growth QoQ from ₹189 cr in Q4 FY23 |
| Profit before exceptional items and tax margin | 31%, compared to 36% in Q1 FY23 which was exceptional |
| Export growth (Q1 FY23) | +30% YoY, driven by volume, favourable FX, and freight-related gross margin benefit |
| Exceptional items: gain on asset sale (Q1 FY23) | ~₹18 cr |
| Exceptional items: severance costs (Emcure/Cipla partnerships) | ~₹27 cr |
| Other income (Q1 FY23) | ~₹19 cr, from interest on bank deposits and income tax refund |
| Consumer Healthcare sales contribution | ~30% of total company sales, unaudited |
| Consumer Healthcare operating profit contribution | 37% to 39% of total, unaudited, could vary by 1 ppt |
| Basal insulin market share | 38% |
| Total insulin market share | 8% (per an analyst's math) |
| Premix insulin market size | ~₹1,000 cr |
| Basal insulin market size | ~₹1,000 cr |
| Employee count (FY23) | ~2,100, down from ~2,600 in FY22 |